ArticleJACC. Advances2026
Truncating Titin and Lamin A/C Variants in Anthracycline-Induced Cardiomyopathy.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnthracycline chemotherapy-related cardiomyopathy (CCM) is a serious adverse event that can occur several years after completion of therapy. Demographic and clinical risk factors have failed to predict which patients will experience CCM. Genetic variants may account for a significant proportion of interindividual variation and CCM.
objectivesThis study aimed to identify genetic variants in the known idiopathic cardiomyopathy genes that predispose patients to CCM.
methodsWe developed a cardiotoxicity registry. Patients were (and continue to be) enrolled and consented for chart review and DNA sequencing. We sequenced whole exomes of the first 136 patients (anthracycline, n = 55; anti-HER2 [no anthracycline], n = 71; other chemotherapy, n = 10), primarily focusing on titin (TTN) truncating variants, known to be present in ∼25% of patients with primary dilated cardiomyopathy, and previously reported in 7.5% of patients with CCM, followed by exploration of rare nonsynonymous variants in 62 established genes for idiopathic cardiomyopathy.
resultsEighteen of 55 patients treated with anthracycline experienced CCM. TTN truncating variants were identified in 2 of 18 (11%) CCM patients and absent in 37 patients who did not experience CCM. We identified a pathogenic variant in lamin A/C (p.Arg190Gln) in 1/18 (5.5%) patients and the same rare (p.Glu1127Gly) variant in ryanodine receptor 2 occurred in 2/18 (11%) of patients. We observed enrichment of rare missense variants in patients with anthracycline CCM compared to anti-HER2 therapy without anthracycline CCM (P < 0.00001).
conclusionsThree of 18 anthracycline CCM patients carried likely pathogenic variants in the most common causative genes for idiopathic dilated cardiomyopathy, TTN, and lamin A/C. Rare nonsynonymous variants in ryanodine receptor 2 and other idiopathic cardiomyopathy genes warrant further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.